<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:03:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5947451" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5947451</identifier>
        <datestamp>2018-05-15</datestamp>
        <setSpec>oncologist</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Oncologist</journal-id>
              <journal-id journal-id-type="iso-abbrev">Oncologist</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id>
              <journal-id journal-id-type="publisher-id">The Oncologist</journal-id>
              <journal-id journal-id-type="pmc">oncologist</journal-id>
              <journal-id journal-id-type="hwp">theoncologist</journal-id>
              <journal-title-group>
                <journal-title>The Oncologist</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1083-7159</issn>
              <issn pub-type="epub">1549-490X</issn>
              <publisher>
                <publisher-name>AlphaMed Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5947451</article-id>
              <article-id pub-id-type="pmcid">PMC5947451</article-id>
              <article-id pub-id-type="pmc-uid">5947451</article-id>
              <article-id pub-id-type="pmid">29371473</article-id>
              <article-id pub-id-type="doi">10.1634/theoncologist.2017-0661</article-id>
              <article-id pub-id-type="publisher-id">ONCO12367</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>4</subject>
                  <subject>11</subject>
                  <subject>31</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Trial Results</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas</article-title>
              </title-group>
              <contrib-group>
                <contrib id="onco12367-cr-0001" contrib-type="author">
                  <name>
                    <surname>William</surname>
                    <given-names>William N.</given-names>
                    <suffix>Jr.</suffix>
                  </name>
                  <address>
                    <email>williamwilliamjr@gmail.com</email>
                  </address>
                  <xref ref-type="correspondence-address" rid="correspondenceTo">*</xref>
                  <xref ref-type="aff" rid="onco12367-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12367-cr-0002" contrib-type="author">
                  <name>
                    <surname>Tsao</surname>
                    <given-names>Anne S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12367-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12367-cr-0003" contrib-type="author">
                  <name>
                    <surname>Feng</surname>
                    <given-names>Lei</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12367-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12367-cr-0004" contrib-type="author">
                  <name>
                    <surname>Ginsberg</surname>
                    <given-names>Lawrence E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12367-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12367-cr-0005" contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>J. Jack</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12367-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12367-cr-0006" contrib-type="author">
                  <name>
                    <surname>Kies</surname>
                    <given-names>Merrill S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12367-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12367-cr-0007" contrib-type="author">
                  <name>
                    <surname>Glisson</surname>
                    <given-names>Bonnie S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12367-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12367-cr-0008" contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Edward S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12367-aff-0002">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <aff id="onco12367-aff-0001"><label><sup>a</sup></label><institution>The University of Texas MD Anderson Cancer Center</institution>, <city>Houston</city>, <state>Texas</state>, <country country="US">USA</country></aff>
                <aff id="onco12367-aff-0002"><label><sup>b</sup></label><institution>Levine Cancer Institute</institution>, <city>Charlotte</city>, <state>North Carolina</state>, <country country="US">USA</country></aff>
              </contrib-group>
              <author-notes>
                <fn id="onco12367-note-0001" fn-type="COI-statement">
                  <p><italic>Disclosures of potential conflicts of interest may be found at the end of this article</italic>.</p>
                </fn>
                <corresp id="correspondenceTo"><label>*</label>Correspondence: William N. William Jr., M.D., The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, Texas 77030, USA. Telephone: 713‐792‐6363; e‐mail: <email>williamwilliamjr@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>25</day>
                <month>1</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>5</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>25</day>
                <month>1</month>
                <year>2018</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>23</volume>
              <issue>5</issue>
              <issue-id pub-id-type="doi">10.1002/onco.v23.5</issue-id>
              <fpage>526</fpage>
              <lpage>e49</lpage>
              <history>
                <date date-type="received">
                  <day>07</day>
                  <month>11</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>12</day>
                  <month>12</month>
                  <year>2017</year>
                </date>
              </history>
              <permissions>
                <copyright-statement content-type="article-copyright">©AlphaMed Press; the data published online to support this summary is the property of the authors</copyright-statement>
              </permissions>
              <self-uri content-type="pdf" xlink:href="onco12367.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="onco12367-sec-0097">
                  <title>Lessons Learned.</title>
                  <p>
                    <list list-type="bullet" id="onco12367-list-0001">
                      <list-item id="onco12367-li-0001">
                        <p>The combination of cisplatin, docetaxel, and erlotinib as frontline treatment for recurrent and/or metastatic head and neck squamous cell carcinomas led to a response rate of 62%.</p>
                      </list-item>
                      <list-item id="onco12367-li-0002">
                        <p>This result exceeded the prespecified target response rate of 50% and represented an improvement compared with historical controls.</p>
                      </list-item>
                      <list-item id="onco12367-li-0003">
                        <p>This regimen warrants further investigation.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
                <sec id="onco12367-sec-0090">
                  <title>Background.</title>
                  <p>The epidermal growth factor receptor (EGFR) plays a key role in the carcinogenesis of head and neck squamous cell carcinomas (HNSCC). We conducted this clinical study to test the hypothesis that the addition of erlotinib to first‐line cisplatin and docetaxel for patients with recurrent and/or metastatic HNSCC would yield a response rate of at least 50%, representing an improvement from historical controls.</p>
                </sec>
                <sec id="onco12367-sec-0091">
                  <title>Methods.</title>
                  <p>Patients with recurrent and/or metastatic HNSCC, with at least one measurable lesion, no prior chemotherapy for recurrent and/or metastatic disease, prior combined modality therapy completed &gt;6 months before enrollment, and performance status ≤2 were treated with cisplatin, docetaxel, and erlotinib for up to six cycles, followed by maintenance erlotinib until disease progression. The primary endpoint was response rate.</p>
                </sec>
                <sec id="onco12367-sec-0092">
                  <title>Results.</title>
                  <p>Fifty patients were enrolled (42 male, 12 never smokers, 19 with oropharynx cancer). The median number of cycles was five; 31 patients initiated maintenance erlotinib; 14 patients required erlotinib dose reductions. The objective response rate was 62%, and the median progression‐free and overall survival were 6.1 and 11.0 months, respectively. Toxicity profiles were consistent with the known side effects of the study drugs.</p>
                </sec>
                <sec id="onco12367-sec-0093">
                  <title>Conclusion.</title>
                  <p>The study met its primary endpoint and improved response rates compared with historical controls. The findings support further evaluation of the regimen for recurrent and/or metastatic HNSCCs.</p>
                </sec>
              </abstract>
              <trans-abstract xml:lang="zh" abstract-type="main">
                <p xml:lang="zh">
                  <bold>经验总结</bold>
                </p>
                <p xml:lang="zh">
                  <list list-type="bullet" id="onco12367-list-1002">
                    <list-item id="onco12367-li-1005">
                      <p>将顺铂、多西他赛联合埃罗替尼作为复发性和/或转移性头颈部鳞状细胞癌的一线治疗, 缓解率为62%。</p>
                    </list-item>
                    <list-item id="onco12367-li-1006">
                      <p>此结果高于预先设定的目标缓解率50%, 表示与历史对照相比有所改善。</p>
                    </list-item>
                    <list-item id="onco12367-li-1007">
                      <p>此方案需进行进一步考察。</p>
                    </list-item>
                  </list>
                </p>
                <p xml:lang="zh">
                  <bold>摘要</bold>
                </p>
                <p xml:lang="zh"><bold><italic>背景</italic>.</bold>表皮生长因子受体（EGFR）在头颈部鳞状细胞癌（HNSCC）癌变中起关键作用。我们开展此临床研究的目的是检验以下假设：向复发性和/或转移性HNSCC患者的一线顺铂和多西他赛治疗中添加埃罗替尼得到的缓解率为至少50%, 表示相对于历史对照有所改善。</p>
                <p xml:lang="zh"><bold><italic>方法</italic>.</bold>复发性和/或转移性HNSCC患者（存在至少一处可测量病灶, 未接受过针对复发性和/或转移性疾病的既往化疗, 在入组之前&gt;6个月完成了既往综合治疗且体能状态≤2）接受顺铂、多西他赛和埃罗替尼治疗多达六个周期, 随后接受埃罗替尼维持治疗, 直至出现疾病进展。主要终点是缓解率。</p>
                <p xml:lang="zh"><bold><italic>结果</italic>.</bold>50例患者入组研究（42例男性, 12例从不吸烟, 19例患有口咽癌）。治疗周期中位数为5, 31例患者开始接受埃罗替尼维持治疗；14例患者需要降低埃罗替尼剂量。客观缓解率为62%, 中位无进展生存期和总生存期分别为6.1个月和11.0个月。毒性特征与研究药物的已知副作用一致。</p>
                <p xml:lang="zh"><bold><italic>结论</italic>.</bold>该研究达到其主要终点, 且与历史对照相比缓解率有所改善。这些结果可为针对复发性和/或转移性HNSCC治疗方案的进一步评价提供支持。</p>
              </trans-abstract>
              <counts>
                <page-count count="7"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="discussion" id="onco12367-sec-0094">
              <title>Discussion</title>
              <p>This single‐arm, single‐institution, phase II study was designed to test the hypothesis that the addition of erlotinib to first‐line cisplatin and docetaxel for patients with recurrent and/or metastatic HNSCC would yield a response rate of at least 50%, representing an improvement over historical controls (the response rate to cisplatin and docetaxel alone observed in a previous trial led by the MD Anderson Cancer Center was 40%). The primary endpoint of the study was met, with an observed objective response rate of 62%. Moreover, the median progression‐free survival (6.1 months) and overall survival (11.0 months) achieved by our patient cohort compared favorably with historical controls with chemotherapy alone.</p>
              <p>These results are in accordance with a phase I/II clinical trial evaluating the combination of cisplatin and erlotinib in this setting, which showed a response rate of 21%, considered to be higher than what would be expected with cisplatin alone. Our data add to the growing body of evidence showing that EGFR tyrosine kinase inhibitors have limited activity as monotherapy but may improve outcomes when combined with cytotoxic agents, especially when given in the frontline setting.</p>
              <p>In addition to tyrosine kinase inhibitors, EGFR antibodies have also been investigated in phase III trials of recurrent and/or metastatic HNSCC. Currently the combination of platinum, 5‐fluorouracil, and cetuximab is considered a standard first‐line treatment, given improvements in response rates (20% vs. 36%), median progression‐free survival (3.3 vs. 5.6 months), and overall survival (7.4 vs. 10.1 months), when compared with platinum plus 5‐fluorouracil alone. The results of our clinical trial are comparable to those obtained with platinum, 5‐fluorouracil, and cetuximab. One advantage of the regimen studied herein is the use of a drug that can be administered orally or via feeding tube, obviating the need for weekly infusions, especially in the maintenance setting for patients who achieve longer‐term disease control. On the other hand, 40% of our patients experienced diarrhea (10%, grade 3 or 4), which probably resulted from additive toxicities of docetaxel and erlotinib and deserves attention and careful support.</p>
              <p>The limited sample size of this trial (with only 19 patients with oropharynx cancer) precludes any conclusions about the efficacy of the regimen in disease that is positive versus negative for human papilloma virus, and this parameter has not been evaluated.</p>
              <p>
                <table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor">
                  <graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12367-tbl-0001">
                    <alt-text>image</alt-text>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </graphic>
                </table-wrap>
              </p>
              <p>In summary, the results presented herein provide support for further investigations of the regimen. Indeed, on the basis of these findings, we launched and completed a randomized, double‐blind, placebo‐controlled phase II study of platinum and docetaxel with or without erlotinib. Results recently presented in abstract form confirmed the superiority of the erlotinib‐containing arm. Taken together, the data from the single‐arm and randomized phase II trials provide strong rationale for the use of platinum, docetaxel, and erlotinib as frontline therapy for recurrent and/or metastatic HNSCCs.</p>
            </sec>
            <sec id="onco12367-sec-0002">
              <title>Trial Information</title>
              <p>
                <def-list list-type="simple" id="onco12367-lp-0001">
                  <def-item>
                    <term id="onco12367-li-0009">
                      <bold>Disease</bold>
                    </term>
                    <def id="onco12367-li-0011">
                      <p>Head and neck cancers</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0012">
                      <bold>Stage of Disease/Treatment</bold>
                    </term>
                    <def id="onco12367-li-0014">
                      <p>Metastatic/advanced</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0015">
                      <bold>Prior Therapy</bold>
                    </term>
                    <def id="onco12367-li-0017">
                      <p>None</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0018">
                      <bold>Type of Study ‐ 1</bold>
                    </term>
                    <def id="onco12367-li-0020">
                      <p>Phase II</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0021">
                      <bold>Type of Study ‐ 2</bold>
                    </term>
                    <def id="onco12367-li-0023">
                      <p>Single arm</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0024">
                      <bold>Primary Endpoint</bold>
                    </term>
                    <def id="onco12367-li-0026">
                      <p>Overall response rate</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0027">
                      <bold>Secondary Endpoint</bold>
                    </term>
                    <def id="onco12367-li-0029">
                      <p>Progression‐free survival</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0030">
                      <bold>Secondary Endpoint</bold>
                    </term>
                    <def id="onco12367-li-0032">
                      <p>Toxicity</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0033">
                      <bold>Additional Details of Endpoints or Study Design</bold>
                    </term>
                    <def id="onco12367-li-0317">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-1091">The overall response rate was the primary endpoint of the study and was determined using RECIST version 1.0. The response status was evaluated after two cycles of treatment and confirmed between 4 and 6 weeks thereafter. A Bayesian design based on predictive probabilities was employed to allow for early stopping if the accumulating evidence suggested treatment ineffectiveness. The maximum calculated sample size was 50 patients, and outcomes were evaluated after the first 15 and 30 patients were treated. If at either interim analysis the predictive probability of a positive study (i.e., posterior probability of response rate &gt;30% at least 90%) was low (&lt;.05), the trial would be stopped. The rule corresponded to stopping the trial if one saw three or fewer responders in 15 patients or 9 or fewer responders in 30 patients. This design provided 92% power with an α of 0.08 to detect a true response rate of 50%.</term>
                    <def id="onco12367-li-1317">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-1191">Eligible patients were required to have histologically or cytologically confirmed metastatic or recurrent head and neck squamous cell carcinoma, with at least one measurable lesion according to RECIST version 1.0; no prior chemotherapy for metastatic or recurrent disease; completed prior combined modality therapy for at least 6 months; Eastern Cooperative Oncology Group (ECOG) performance status &lt;2; and normal organ and marrow function, including leukocytes &gt;3,000/µL, absolute neutrophil count &gt;1,500/µL, platelets &gt;100,000/µL, hemoglobin ≥ 8 g/dL, total bilirubin within normal institutional limits, aspartate aminotransferase/alanine aminotransferase &lt;2.5 × the institutional upper limit of normal (ULN) if alkaline phosphatase is &lt;ULN (alkaline phosphatase may be up to 4 × ULN if transaminases are &lt;ULN), creatinine &lt;2.0 × ULN or creatinine clearance &gt;60 mL/min/1.73 m<sup>2</sup> for patients with creatinine level above institutional normal. Exclusion criteria included HNSCC of the nasopharynx; history of nonpalliative radiation for metastatic and/or recurrent disease; prior anti‐EGFR biologic therapy; brain metastases; pre‐existing grade 2 or greater peripheral neuropathy (by the National Cancer Institute Common Terminology Criteria version 2.0); or uncontrolled intercurrent illness.</term>
                    <def id="onco12367-li-0035">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0039">
                      <bold>Investigator's Analysis</bold>
                    </term>
                    <def id="onco12367-li-0041">
                      <p>Active and should be pursued further</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12367-sec-0003">
              <title>Drug Information</title>
              <p>
                <def-list list-type="simple" id="onco12367-lp-0002">
                  <def-item>
                    <term id="onco12367-li-0042">
                      <bold>Drug 1</bold>
                    </term>
                    <def id="onco12367-li-0044">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0045">Generic/Working Name</term>
                    <def id="onco12367-li-0047">
                      <p>Cisplatin</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0048">
                      <bold>Drug Type</bold>
                    </term>
                    <def id="onco12367-li-0050">
                      <p>Small molecule</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0051">
                      <bold>Drug Class</bold>
                    </term>
                    <def id="onco12367-li-0053">
                      <p>Platinum compound</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0054">
                      <bold>Dose</bold>
                    </term>
                    <def id="onco12367-li-0056">
                      <p>75 milligrams (mg) per square meter (m<sup>2</sup>)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0057">
                      <bold>Route</bold>
                    </term>
                    <def id="onco12367-li-0059">
                      <p>IV</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0060">
                      <bold>Schedule of Administration</bold>
                    </term>
                    <def id="onco12367-li-0061">
                      <p>On day 1 every 21 days for a maximum of six cycles</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0062">
                      <bold>Drug 2</bold>
                    </term>
                    <def id="onco12367-li-0064">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0065">
                      <bold>Generic/Working Name</bold>
                    </term>
                    <def id="onco12367-li-0067">
                      <p>Docetaxel</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0068">
                      <bold>Drug Type</bold>
                    </term>
                    <def id="onco12367-li-0070">
                      <p>Small molecule</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0071">
                      <bold>Drug Class</bold>
                    </term>
                    <def id="onco12367-li-0073">
                      <p>Tubulin/microtubules targeting agent</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0074">
                      <bold>Dose</bold>
                    </term>
                    <def id="onco12367-li-0076">
                      <p>60–75 milligrams (mg) per square meter (m<sup>2</sup>)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0077">
                      <bold>Route</bold>
                    </term>
                    <def id="onco12367-li-0079">
                      <p>IV</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0080">
                      <bold>Schedule of Administration</bold>
                    </term>
                    <def id="onco12367-li-1817">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0082">On day 1 every 21 days for a maximum of six cycles. The first six patients received docetaxel 60 mg/m<sup>2</sup>. Escalation of the docetaxel dose to 75 mg/m<sup>2</sup> was allowed for patients experiencing minimal toxicity (grade ≤2) after the first cycle. All subsequent patients were treated with docetaxel 75 mg/m<sup>2</sup>.</term>
                    <def id="onco12367-li-0182">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0083">
                      <bold>Drug 3</bold>
                    </term>
                    <def id="onco12367-li-0085">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0086">
                      <bold>Generic/Working Name</bold>
                    </term>
                    <def id="onco12367-li-0088">
                      <p>Erlotinib</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0089">
                      <bold>Drug Type</bold>
                    </term>
                    <def id="onco12367-li-0091">
                      <p>Biological</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0092">
                      <bold>Drug Class</bold>
                    </term>
                    <def id="onco12367-li-0094">
                      <p>EGFR</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0095">
                      <bold>Dose</bold>
                    </term>
                    <def id="onco12367-li-0097">
                      <p>100–150 milligrams (mg) per flat dose</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0098">
                      <bold>Route</bold>
                    </term>
                    <def id="onco12367-li-0100">
                      <p>Oral</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0101">
                      <bold>Schedule of Administration</bold>
                    </term>
                    <def id="onco12367-li-1517">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0111">Once daily, continuous dosing. The first six patients received erlotinib 100 mg/day. Escalation of the erlotinib dose to 150 mg/day was allowed for patients experiencing minimal toxicity (grade 2) after the first cycle. All subsequent patients were treated with erlotinib 150 mg/day.</term>
                    <def id="onco12367-li-0103">
                      <p> </p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12367-sec-0004">
              <title>Patient Characteristics</title>
              <p>
                <def-list list-type="simple" id="onco12367-lp-0003">
                  <def-item>
                    <term id="onco12367-li-0104">
                      <bold>Number of Patients, Male</bold>
                    </term>
                    <def id="onco12367-li-0105">
                      <p>
                        <bold>42</bold>
                      </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0106">
                      <bold>Number of Patients, Female</bold>
                    </term>
                    <def id="onco12367-li-0107">
                      <p>
                        <bold>8</bold>
                      </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0108">
                      <bold>Stage</bold>
                    </term>
                    <def id="onco12367-li-0110">
                      <p>Locoregional recurrence: 31 patients Metastatic disease: 19 patients</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0114">
                      <bold>Age</bold>
                    </term>
                    <def id="onco12367-li-0116">
                      <p>Median (range): 57</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0117">
                      <bold>Number of Prior Systemic Therapies</bold>
                    </term>
                    <def id="onco12367-li-0118">
                      <p>0</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0119">
                      <bold>Performance Status: ECOG</bold>
                    </term>
                    <def id="onco12367-li-0121">
                      <p>0 — 7</p>
                      <p>1 — 41</p>
                      <p>2 — 2</p>
                      <p>3 —</p>
                      <p>Unknown —</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-1117">Additional details for Patient and Treatment Characteristics can be found in Tables 1 and 2.</term>
                    <def id="onco12367-li-1118">
                      <p> </p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12367-sec-0005">
              <title>Primary Assessment Method</title>
              <p>
                <def-list list-type="simple" id="onco12367-lp-0004">
                  <def-item>
                    <term id="onco12367-li-0134">
                      <bold>Title</bold>
                    </term>
                    <def id="onco12367-li-0136">
                      <p>Total Patient Population</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0137">
                      <bold>Number of Patients Screened</bold>
                    </term>
                    <def id="onco12367-li-0138">
                      <p>50</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0139">
                      <bold>Number of Patients Enrolled</bold>
                    </term>
                    <def id="onco12367-li-0140">
                      <p>50</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0141">
                      <bold>Number of Patients Evaluable for Toxicity</bold>
                    </term>
                    <def id="onco12367-li-0142">
                      <p>50</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0143">
                      <bold>Number of Patients Evaluated for Efficacy</bold>
                    </term>
                    <def id="onco12367-li-0144">
                      <p>50</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0145">Evaluation Method</term>
                    <def id="onco12367-li-0147">
                      <p>RECIST version 1.0</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0148">
                      <bold>Response Assessment CR</bold>
                    </term>
                    <def id="onco12367-li-0150">
                      <p><italic>n</italic> = 4 (8%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0151">
                      <bold>Response Assessment PR</bold>
                    </term>
                    <def id="onco12367-li-0153">
                      <p><italic>n</italic> = 27 (54%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0154">
                      <bold>Response Assessment SD</bold>
                    </term>
                    <def id="onco12367-li-0156">
                      <p><italic>n</italic> = 13 (26%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0157">
                      <bold>Response Assessment PD</bold>
                    </term>
                    <def id="onco12367-li-0159">
                      <p><italic>n</italic> = 3 (6%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0160">
                      <bold>Response Assessment Other</bold>
                    </term>
                    <def id="onco12367-li-0162">
                      <p><italic>n</italic> = 3 (6%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0163">
                      <bold>(Median) Duration Assessments PFS</bold>
                    </term>
                    <def id="onco12367-li-0165">
                      <p>6.11 months, CI: 5.32–7.59</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0166">
                      <bold>(Median) Duration Assessments OS</bold>
                    </term>
                    <def id="onco12367-li-0168">
                      <p>11.0 months, CI: 8.28–14.9</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0169">
                      <bold>(Median) Duration Assessments Response Duration</bold>
                    </term>
                    <def id="onco12367-li-0171">
                      <p>4.89 months</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12367-sec-0006">
              <title>Phase II Experimental Arm Adverse Events</title>
              <p>
                <table-wrap id="nlm-table-wrap-2" xml:lang="en" orientation="portrait" position="anchor">
                  <graphic id="nlm-graphic-3" specific-use="sourcefile-name" xlink:href="onco12367-tbl-0002">
                    <alt-text>image</alt-text>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </graphic>
                  <table-wrap-foot>
                    <fn id="onco12367-note-0003">
                      <p>Fever of unknown origin without clinically or microbiologically documented infection (ANC &lt;1.0 x 10e9/L, fever ≥38.5 degrees C).</p>
                    </fn>
                    <fn id="onco12367-note-0104">
                      <p>Abbreviations: AGC, agranulocytosis; ALT, alanine aminotransferase; ANC, absolute neutrophil count; NC/NA, no change from baseline/no adverse event; SGPT, serum glutamic pyruvic transaminase.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </p>
            </sec>
            <sec id="onco12367-sec-0007">
              <title>Assessment, Analysis, and Discussion</title>
              <p>
                <def-list list-type="simple" id="onco12367-lp-0005">
                  <def-item>
                    <term id="onco12367-li-0172">Completion</term>
                    <def id="onco12367-li-0174">
                      <p>Study completed</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12367-li-0175">Investigator's Assessment</term>
                    <def id="onco12367-li-0177">
                      <p>Active and should be pursued further</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12367-sec-1013">
              <p>This single‐arm, single‐institution, phase II study was designed to test the hypothesis that the addition of erlotinib to first‐line cisplatin and docetaxel for patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) would yield a response rate of at least 50%, representing an improvement over historical controls (the response rate to cisplatin and docetaxel alone observed in a previous trial led by the MD Anderson Cancer Center was 40% [<xref rid="onco12367-bib-0001" ref-type="ref">1</xref>]). The primary endpoint of the study was met, with an observed objective response rate of 62%. Moreover, the median progression‐free (6.1 months) (Fig. 1) and overall (11.0 months) (Fig. 2) survival achieved by our patient cohort compared favorably with historical controls with chemotherapy alone [<xref rid="onco12367-bib-0001" ref-type="ref">1</xref>].</p>
              <p>This clinical trial was designed at a time when there was limited evidence of the activity of epidermal growth factor receptor (EGFR)‐targeted agents in HNSCCs, especially in regard to tyrosine kinase inhibitors (TKIs) combined with chemotherapy. During the conduct and after completion of this study, evidence arose that EGFR TKIs as single agents had modest activity in HNSCC progressing after platinum‐based therapy. Soulieres at al. demonstrated a response rate of 4.3% with single‐agent erlotinib [<xref rid="onco12367-bib-0002" ref-type="ref">2</xref>]. The response rate to single‐agent gefitinib at a dose of 500 mg per day was 10.6% [<xref rid="onco12367-bib-0003" ref-type="ref">3</xref>]. At a lower dose of 250 mg per day, it was 1.4% [<xref rid="onco12367-bib-0004" ref-type="ref">4</xref>]. Gefitinib was subsequently compared with methotrexate in a phase III study and showed a response rate of 2.7% at 250 mg per day and 7.6% at 500 mg per day but failed to improve survival compared with the chemotherapy arm [<xref rid="onco12367-bib-0005" ref-type="ref">5</xref>]. Afatinib elicited a response rate of 10% and improved progression‐free survival (but not overall survival) over methotrexate in a phase III study [<xref rid="onco12367-bib-0006" ref-type="ref">6</xref>]. Taken together, these data do not support the use of monotherapy with an EGFR TKI in pretreated HNSCC.</p>
              <p>Strategies to improve the efficacy of these drugs included investigations of EGFR TKIs earlier in the course of the disease and/or combinations with cytotoxic agents. Our group [<xref rid="onco12367-bib-0007" ref-type="ref">7</xref>] and others [<xref rid="onco12367-bib-0008" ref-type="ref">8</xref>] demonstrated, for example, in separate studies in platinum‐naïve, early stage, resectable HNSCC, that erlotinib was associated with response rates of 25%–29%, suggesting that the timing of EGFR TKI exposure may influence activity. Indeed, in the current clinical trial, erlotinib was given as first‐line therapy for recurrent and/or metastatic disease, in patients with no recent exposure to platinum, and showed improved efficacy compared with historical controls. These results are in accordance with a phase I/II clinical trial evaluating the combination of cisplatin and erlotinib in this setting, which showed a response rate of 21%, considered to be higher than what would be expected with cisplatin alone, although the study did not meet the overly optimistic, prespecified target response rate improvement [<xref rid="onco12367-bib-0009" ref-type="ref">9</xref>]. In contrast, a phase II study in previously treated patients with recurrent and/or metastatic HNSCC showed no benefits of adding gefitinib to docetaxel in regard to survival or response rates [<xref rid="onco12367-bib-0010" ref-type="ref">10</xref>], again indicating that the use of EGFR TKIs in later lines of therapy may result in suboptimal outcomes.</p>
              <p>In addition to TKIs, EGFR antibodies have also been investigated in phase III trials of recurrent and/or metastatic HNSCC [<xref rid="onco12367-bib-0011" ref-type="ref">11</xref>], [<xref rid="onco12367-bib-0012" ref-type="ref">12</xref>], [<xref rid="onco12367-bib-0013" ref-type="ref">13</xref>]. Currently, the combination of platinum, 5‐fluorouracil, and cetuximab is considered a standard first‐line treatment, given improvements in response rates (20% vs. 36%), median progression‐free survival (3.3 vs. 5.6 months) and overall survival (7.4 vs. 10.1 months), when compared with platinum plus 5‐fluorouracil alone [<xref rid="onco12367-bib-0012" ref-type="ref">12</xref>]. The results of our clinical trial are comparable to those obtained with platinum, 5‐fluorouracil, and cetuximab. One advantage of the regimen studied herein is the use of a drug that can be administered orally or via feeding tube, obviating the need for weekly infusions, especially in the maintenance setting for patients who achieve longer‐term disease control. On the other hand, 40% of our patients experienced diarrhea (10%, grade 3 or 4), which probably resulted from additive toxicities of docetaxel and erlotinib and deserves attention and careful support.</p>
              <p>In an attempt to maximize benefit‐risk ratios of EGFR inhibitors in HNSCCs, several groups have investigated candidate biomarkers of efficacy. Human papilloma virus (HPV) status was not found to be a predictive marker of benefit from cetuximab added to platinum and 5‐fluorouracil in one phase III study [<xref rid="onco12367-bib-0014" ref-type="ref">14</xref>]. In the randomized trial of platinum, 5‐fluorouracil, and panitumumab, the addition of the EGFR antibody was associated with a trend toward improved outcomes primarily in the p16‐negative subgroup [<xref rid="onco12367-bib-0013" ref-type="ref">13</xref>] (although p16 scoring criteria in that study was different than what has been used in pivotal trials in locally advanced disease). Our study only included 19 patients with oropharynx cancers and we did not evaluate HPV/p16 status. However, given the small sample size and nonrandomized nature of this study, analysis of efficacy according to HPV status would likely be unable to provide meaningful conclusions. EGFR copy number gain failed as a predictive marker of benefit from cetuximab or gefitinib in the phase III studies [<xref rid="onco12367-bib-0005" ref-type="ref">5</xref>], [<xref rid="onco12367-bib-0015" ref-type="ref">15</xref>], indicating that the search for biomarkers in this setting is not straightforward and may require a comprehensive evaluation of multiple pathways, an effort that is currently underway using specimens collected during this study.</p>
              <p>In summary, we demonstrated herein that the addition of erlotinib to first‐line cisplatin and docetaxel led to improved response rates compared with historical controls. This clinical trial met its primary endpoint, providing support for further investigations of this regimen. Indeed, on the basis of these findings, we launched and completed a randomized, double‐blind, placebo‐controlled phase II study of platinum and docetaxel with or without erlotinib. Results recently presented in abstract form confirmed the superiority of the erlotinib‐containing arm [<xref rid="onco12367-bib-0016" ref-type="ref">16</xref>]. Taken together, the data from the described single‐arm phase II trial and the randomized phase II trials provide a strong rationale for the use of platinum, docetaxel, and erlotinib as frontline therapy for recurrent and/or metastatic HNSCCs.</p>
            </sec>
            <sec id="onco12367-sec-1117">
              <title>Figures and Tables</title>
              <fig fig-type="Figure" xml:lang="en" id="onco12367-fig-0001" orientation="portrait" position="float">
                <label>Figure 1.</label>
                <caption>
                  <p>Progression‐free survival (bold line) and 95% confidence interval (dotted lines).</p>
                </caption>
                <graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12367-fig-0001">
                  <alt-text>image</alt-text>
                </graphic>
              </fig>
              <fig fig-type="Figure" xml:lang="en" id="onco12367-fig-0002" orientation="portrait" position="float">
                <label>Figure 2.</label>
                <caption>
                  <p>Overall survival (bold line) and 95% confidence interval (dotted lines).</p>
                </caption>
                <graphic id="nlm-graphic-9" specific-use="sourcefile-name" xlink:href="onco12367-fig-0002">
                  <alt-text>image</alt-text>
                </graphic>
              </fig>
              <table-wrap id="onco12367-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                <label>Table 1.</label>
                <caption>
                  <title>Patient characteristics</title>
                </caption>
                <graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12367-tbl-0003">
                  <alt-text>image</alt-text>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                  </permissions>
                </graphic>
              </table-wrap>
              <table-wrap id="onco12367-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                <label>Table 2.</label>
                <caption>
                  <title>Treatment characteristics</title>
                </caption>
                <graphic id="nlm-graphic-15" specific-use="sourcefile-name" xlink:href="onco12367-tbl-0004">
                  <alt-text>image</alt-text>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                  </permissions>
                </graphic>
              </table-wrap>
            </sec>
          </body>
          <back>
            <ack id="onco12367-sec-0008">
              <title>Acknowledgments</title>
              <p>This work was supported by NIH grant P30 CA016672, Cancer Prevention Research Institute of Texas grant RP140464, and a grant from the Conquer Cancer Foundation.</p>
            </ack>
            <fn-group>
              <fn fn-type="other" id="onco12367-note-2201">
                <p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00076310">NCT00076310</ext-link></p>
                <p><bold>Sponsor(s)</bold>: Genentech, OSI Pharmaceuticals, and Sanofi Aventis</p>
                <p><bold>Principal Investigator</bold>: William Nassib William Jr.</p>
                <p><bold>IRB Approved</bold>: Yes</p>
              </fn>
              <fn id="onco12367-note-4392">
                <p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p>
              </fn>
            </fn-group>
            <sec id="onco12367-sec-0009" sec-type="disclosure">
              <title>Disclosures</title>
              <p><bold>William N. William Jr.:</bold> Roche/Genentech (C/A), Astellas Pharmaceuticals, Eli Lilly, Bristol‐Meyers Squibb, Merck, Astellas Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals (RF), AstraZeneca, Roche, Genentech (H); <bold>Anne S. Tsao:</bold> Boehringer‐Ingelheim Pharmaceuticals, Bristol‐Myers Squibb, EMD Serono, Genentech BioOncology, Eli Lilly, Merck, Novartis, Roche Laboratories, Takeda Oncology (C/A), Boehringer‐Ingelheim Pharmaceuticals, Bristol‐Meyers Squibb, Genentech, Eli Lilly, Merck (RF). The other authors indicated no financial relationships.</p>
              <p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p>
            </sec>
            <ref-list content-type="cited-references">
              <title>References</title>
              <ref id="onco12367-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0001"><string-name><surname>Glisson</surname><given-names>BS</given-names></string-name>, 
<string-name><surname>Murphy</surname><given-names>BA</given-names></string-name>, 
<string-name><surname>Frenette</surname><given-names>G</given-names></string-name> et al. <article-title>Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2002</year>;<volume>20</volume>:<fpage>1593</fpage>–<lpage>1599</lpage>.
<pub-id pub-id-type="pmid">11896109</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0002"><string-name><surname>Soulieres</surname><given-names>D</given-names></string-name>, 
<string-name><surname>Senzer</surname><given-names>NN</given-names></string-name>, 
<string-name><surname>Vokes</surname><given-names>EE</given-names></string-name> et al. <article-title>Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2004</year>;<volume>22</volume>:<fpage>77</fpage>–<lpage>85</lpage>.
<pub-id pub-id-type="pmid">14701768</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0003"><string-name><surname>Cohen</surname><given-names>EE</given-names></string-name>, 
<string-name><surname>Rosen</surname><given-names>F</given-names></string-name>, 
<string-name><surname>Stadler</surname><given-names>WM</given-names></string-name> et al. <article-title>Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2003</year>;<volume>21</volume>:<fpage>1980</fpage>–<lpage>1987</lpage>.
<pub-id pub-id-type="pmid">12743152</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0004"><string-name><surname>Cohen</surname><given-names>EE</given-names></string-name>, 
<string-name><surname>Kane</surname><given-names>MA</given-names></string-name>, 
<string-name><surname>List</surname><given-names>MA</given-names></string-name> et al. <article-title>Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck</article-title>. <source xml:lang="en">Clin Cancer Res</source>
<year>2005</year>;<volume>11</volume>:<fpage>8418</fpage>–<lpage>8424</lpage>.
<pub-id pub-id-type="pmid">16322304</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0005"><string-name><surname>Stewart</surname><given-names>JS</given-names></string-name>, 
<string-name><surname>Cohen</surname><given-names>EE</given-names></string-name>, 
<string-name><surname>Licitra</surname><given-names>L</given-names></string-name> et al. <article-title>Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>1864</fpage>–<lpage>1871</lpage>.
<pub-id pub-id-type="pmid">19289630</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0006"><string-name><surname>Machiels</surname><given-names>JP</given-names></string-name>, 
<string-name><surname>Haddad</surname><given-names>RI</given-names></string-name>, 
<string-name><surname>Fayette</surname><given-names>J</given-names></string-name> et al. <article-title>Afatinib versus methotrexate as second‐line treatment in patients with recurrent or metastatic squamous‐cell carcinoma of the head and neck progressing on or after platinum‐based therapy (LUX‐Head &amp; Neck 1): An open‐label, randomised phase 3 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>
<year>2015</year>;<volume>16</volume>:<fpage>583</fpage>–<lpage>594</lpage>.
<pub-id pub-id-type="pmid">25892145</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0007"><string-name><surname>William</surname><given-names>WN</given-names><suffix>Jr</suffix></string-name>, 
<string-name><surname>Weber</surname><given-names>RS</given-names></string-name>, 
<string-name><surname>Lee</surname><given-names>JJ</given-names></string-name> et al. <chapter-title>Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes</chapter-title>
<source xml:lang="en">J Clin Oncol</source>
<year>2011</year>;<volume>29</volume>(<issue>suppl 15</issue>):<fpage>5520A</fpage>.
</mixed-citation>
              </ref>
              <ref id="onco12367-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0008"><string-name><surname>Thomas</surname><given-names>F</given-names></string-name>, 
<string-name><surname>Rochaix</surname><given-names>P</given-names></string-name>, 
<string-name><surname>Benlyazid</surname><given-names>A</given-names></string-name> et al. <article-title>Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma</article-title>. <source xml:lang="en">Clin Cancer Res</source>
<year>2007</year>;<volume>13</volume>:<fpage>7086</fpage>–<lpage>7092</lpage>.
<pub-id pub-id-type="pmid">18056187</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0009"><string-name><surname>Siu</surname><given-names>LL</given-names></string-name>, 
<string-name><surname>Soulieres</surname><given-names>D</given-names></string-name>, 
<string-name><surname>Chen</surname><given-names>EX</given-names></string-name> et al. <article-title>Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada clinical trials group study</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2007</year>;<volume>25</volume>:<fpage>2178</fpage>–<lpage>2183</lpage>.
<pub-id pub-id-type="pmid">17538162</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0010"><string-name><surname>Argiris</surname><given-names>A</given-names></string-name>, 
<string-name><surname>Ghebremichael</surname><given-names>M</given-names></string-name>, 
<string-name><surname>Gilbert</surname><given-names>J</given-names></string-name> et al. <article-title>Phase III randomized, placebo‐controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncology Group trial</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2013</year>;<volume>31</volume>:<fpage>1405</fpage>–<lpage>1414</lpage>.
<pub-id pub-id-type="pmid">23460714</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0011"><string-name><surname>Machiels</surname><given-names>JP</given-names></string-name>, 
<string-name><surname>Subramanian</surname><given-names>S</given-names></string-name>, 
<string-name><surname>Ruzsa</surname><given-names>A</given-names></string-name> et al. <article-title>Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous‐cell carcinoma of the head and neck after failure of platinum‐based chemotherapy: An open‐label, randomised phase 3 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>
<year>2011</year>;<volume>12</volume>:<fpage>333</fpage>–<lpage>343</lpage>.
<pub-id pub-id-type="pmid">21377930</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0012"><string-name><surname>Vermorken</surname><given-names>JB</given-names></string-name>, 
<string-name><surname>Mesia</surname><given-names>R</given-names></string-name>, 
<string-name><surname>Rivera</surname><given-names>F</given-names></string-name> et al. <article-title>Platinum‐based chemotherapy plus cetuximab in head and neck cancer</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2008</year>;<volume>359</volume>:<fpage>1116</fpage>–<lpage>1127</lpage>.
<pub-id pub-id-type="pmid">18784101</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0013"><string-name><surname>Vermorken</surname><given-names>JB</given-names></string-name>, 
<string-name><surname>Stöhlmacher‐Williams</surname><given-names>J</given-names></string-name>, 
<string-name><surname>Davidenko</surname><given-names>I</given-names></string-name> et al. <article-title>Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous‐cell carcinoma of the head and neck (SPECTRUM): An open‐label phase 3 randomised trial</article-title>. <source xml:lang="en">Lancet Oncol</source>
<year>2013</year>;<volume>14</volume>:<fpage>697</fpage>–<lpage>710</lpage>.
<pub-id pub-id-type="pmid">23746666</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0014"><string-name><surname>Vermorken</surname><given-names>JB</given-names></string-name>, 
<string-name><surname>Psyrri</surname><given-names>A</given-names></string-name>, 
<string-name><surname>Mesía</surname><given-names>R</given-names></string-name> et al. <article-title>Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: Retrospective analysis of the phase III EXTREME trial</article-title>. <source xml:lang="en">Ann Oncol</source>
<year>2014</year>;<volume>25</volume>:<fpage>801</fpage>–<lpage>807</lpage>.
<pub-id pub-id-type="pmid">24577117</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0015"><string-name><surname>Licitra</surname><given-names>L</given-names></string-name>, 
<string-name><surname>Mesia</surname><given-names>R</given-names></string-name>, 
<string-name><surname>Rivera</surname><given-names>F</given-names></string-name>, et al. <article-title>Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first‐line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study</article-title>. <source xml:lang="en">Ann Oncol</source><year>2011</year>;<volume>22</volume>:<fpage>1078</fpage>–<lpage>1087</lpage>.
<pub-id pub-id-type="pmid">21048039</pub-id></mixed-citation>
              </ref>
              <ref id="onco12367-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="onco12367-cit-0016"><string-name><surname>William</surname><given-names>WN</given-names></string-name>, 
<string-name><surname>Feng</surname><given-names>L</given-names></string-name>, 
<string-name><surname>Kies</surname><given-names>MS</given-names></string-name> et al. <article-title>Randomized, double‐blind, placebo‐controlled, phase II trial of first‐line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs)</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2017</year>;<volume>35</volume>(<issue>suppl 15</issue>):<fpage>6017A</fpage>.
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
